MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Other Events
Item 8.01 Other Events.
MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Other Events
On February 3, 2020, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its open label, single arm US Phase 1 trial met its primary objective of demonstrating the safety of Liposomal Annamycin (“Annamycin”) in treating relapsed or refractory acute myeloid leukemia (“AML”). The Company also announced an update on interim enrollment, safety and efficacy data in its parallel Phase 1 trial in Europe, which continues with dose escalation, thus far without safety concerns.
A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated February 3, 2020
Moleculin Biotech, Inc. Exhibit
EX-99.1 2 exh991-pressreleaseusphase.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Moleculin Announces Successful Completion of US Phase 1 AML Trial of AnnamycinNo evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients; Company updates interim Phase 1 trial results in EuropeHOUSTON,…
To view the full exhibit click
EX-99.1 2 exh991-pressreleaseusphase.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Moleculin Announces Successful Completion of US Phase 1 AML Trial of AnnamycinNo evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients; Company updates interim Phase 1 trial results in EuropeHOUSTON,…
To view the full exhibit click
hereAbout MOLECULIN BIOTECH, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.
